Guardant Health, Inc.
StreetZero Signal 50
About Guardant Health, Inc.
Guardant Health, Inc. is a leading precision oncology company focused on conquering cancer globally through proprietary blood tests, vast data sets and advanced analytics. Founded in 2012 and headquartered in Palo Alto, California, the company develops digital sequencing technology for cancer detection. It has raised approximately $557 million in total funding over seven rounds before becoming a public company on NASDAQ under ticker GH. The company aims to sequence the DNA of one million cancer patients and accelerate new cancer therapies.
LATEST FUNDINGRule 144
$11K
Announced 2026-10-14
TOTAL RAISED$557M
IN THE NEWS
- 🔗 Guardant Health - Wikipedia
- 🔗 Guardant Health - 2026 Company Profile, Funding, Competitors & Financials - Tracxn
- 🔗 Document
- 🔗 Guardant Health Announces Proposed Public Offering of Common Stock | Guardant Health Investor Relations
- 🔗 Guardant Health Announces Pricing of Upsized Public Offering of Common Stock | Guardant Health Investor Relations
EMPLOYEES—
FOUNDED2012
HQPalo Alto, CA, United States
Industry
Public Equity (NASDAQ)
Tags
Precision OncologyBiotechPublicCancer Diagnostics
Key highlights
- Raised $557M total before IPO with backing from Sequoia and Lightspeed.
- Completed IPO at $19/share generating $220.875M in proceeds.
- Developing blood-based tests and aiming to sequence DNA of 1M cancer patients.
- Public company on NASDAQ: GH with recent secondary offerings announced.
Ask StreetZero about Guardant Health, Inc.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account